Amsterdam's myTomorrows lands €25M to connect more patients with pre-approval treatments. Amsterdam-based myTomorrows raises €25M from Avego Healthcare Capital to expand global access to pre-approval therapies through its AI platform. Amsterdam-based myTomorrows, a health technology company that connects patients with all possible pre-approval treatments, has secured €25M growth equity round with Avego Healthcare Capital (through Avego Healthcare Capital Fund II). Avego is a multi-strategy healthcare-focused investment firm with offices in New York and Georgia. Through its three strategies, which include private equity, venture capital, and a long/short fund, Avego invests in private and public companies developing and commercialising innovative products and services for patients, practitioners, and other stakeholders across the healthcare continuum. "Avego is proud to support myTomorrows in its mission to transform how patients and physicians access therapies in development," says James Flexner, Managing Partner at Avego. "We believe myTomorrows is uniquely positioned to remove barriers for patients and providers while serving as an essential partner to BioPharma." Fund utilisation. The new investment will support the Dutch company's growth in international markets and improve its AI-based platform that connects doctors, patients, trial sites, and BioPharma partners for better access and insights. It will also help strengthen partnerships in the industry, making clinical development faster and improving the use of real-world data for generating evidence and gaining regulatory insights. "This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow's therapies," said Michel van Harten, CEO of myTomorrows. "Avego's extensive expertise in life sciences, particularly BioPharma, will be instrumental as we scale our platform and broaden our impact across the global health landscape." More than 300 million patients worldwide are facing conditions without approved treatment options, and over 10,000 therapies are currently in development or awaiting approval. myTomorrows: connects patients, physicians, trial sites, and BioPharma partners. Led by Michel van Harten, myTomorrows tackles a key challenge in healthcare: helping patients access pre-approval treatments, such as clinical trials and expanded access programs (EAPs), faster. The Dutch company connects patients, doctors, trial sites, and BioPharma partners to improve access to treatments before they are officially approved. Using a centralised platform, the company combines AI insights with human knowledge to create tailored solutions that tackle major barriers to patient access. Ronald Brus, Founder and Board Member of myTomorrows, adds, "When we founded myTomorrows in 2012, we envisioned a better way to connect patients with promising therapies - one that complements drug development and expands access to innovation. This investment marks the beginning of the next phase of accelerated growth and worldwide impact." By simplifying and bringing transparency to the path of discovery and access to treatment, myTomorrows accelerates global patient access while supporting more efficient drug development. Helps with clinical trial recruitment. myTomorrows helps biopharma companies with clinical trial recruitment, expanded access, and collecting real-world data. For trial sites, it offers a referral management system that improves visibility and provides real-time updates. By connecting everyone in the healthcare system and using advanced technology with personalised support, the company speeds up the delivery of new therapies to patients in need. As a main gateway for pre-approval therapies, the Dutch company is creating a new way for patients to access treatments, one that uses AI, adapts to regulations, and empowers patients to be involved in their care. Headquartered in Amsterdam, with an office in New York City, myTomorrows has supported more than 16,900 patients and 2,800 physicians across 340+ sites in over 133 countries.

myTomorrows to use funding to 'transform' patient therapy access. Health technology company myTomorrows has secured $29 million in funding to develop its AI-driven global platform, aiming to bring patients access to innovative therapies. The company aims to develop a platform to bridge the gap between scientific advancement and patient access to pre-approval treatments. This includes drug candidates undergoing clinical trials or expanded access programmes (EAPs). Healthcare investment firm Avego committed to myTomorrows as part of the financing round, which myTomorrows hopes will help connect patients to physicians, trial sites and biopharma partners via its platform. It is hoped the platform can also shorten clinical development timelines and enhance real-world data capabilities. "This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow's therapies," said Michel van Harten, CEO of myTomorrows. "Avego's extensive expertise in life sciences, particularly BioPharma, will be instrumental as we scale our platform and broaden our impact across the global health landscape." "Avego is proud to support myTomorrows in its mission to transform how patients and physicians access therapies in development," added James Flexner, Managing Partner at Avego. "We believe myTomorrows is uniquely positioned to remove barriers for patients and providers while serving as an essential partner to biopharma." According to myTomorrows, the company has helped nearly 17,000 patients across 133 countries, supporting patients and physicians with navigation services, treatment matching, and streamlined access to clinical trials and EAPs.

Amsterdam-based myTomorrows has secured $29M in funding from Avego to enhance its AI-powered platform that connects patients, doctors, clinical trial sites, and pharmaceutical companies. The investment will help the company expand into new markets, strengthen industry collaborations, and improve its real-world data capabilities, aiming to provide global access to experimental treatments for patients lacking approved therapies.